Full Text View
Tabular View
No Study Results Posted
Related Studies
RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
This study is ongoing, but not recruiting participants.
Study NCT00629525   Information provided by Duke University
First Received: February 27, 2008   Last Updated: September 15, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hormone Refractory Prostate Cancer
Additional conditions recognized in this trial
Prostatic Neoplasms
More general conditions related to this trial
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Interventions listed in this trial
RAD001
Additional drug interventions recognized in this trial
Everolimus
More general drug interventions related to this trial
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Duke University
Novartis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services